AMEX:EHC - Encompass Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $92.18
  • Forecasted Upside:
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Encompass Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EHC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$92.18
▲ +∞ Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is $92.18, with a high forecast of $106.00 and a low forecast of $83.00. The average price target represents a ∞ upside from the last price of $0.00.
Buy
The current consensus among 11 polled investment analysts is to buy stock in Encompass Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/28/2021Credit Suisse GroupLower Price TargetOutperform$97.00 ➝ $92.00
i
1/28/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$70.00 ➝ $87.00
i
1/15/2021UBS GroupBoost Price TargetBuy$85.00 ➝ $106.00
i
12/18/2020MizuhoBoost Price TargetBuy$87.00 ➝ $90.00
i
11/30/2020Raymond JamesBoost Price TargetOutperform$78.00 ➝ $90.00
i
11/23/2020BarclaysUpgradeEqual Weight ➝ Overweight$96.00
i
11/2/2020Credit Suisse GroupLower Price TargetOutperform$89.00 ➝ $85.00
i
11/2/2020Raymond JamesLower Price TargetOutperform$86.00 ➝ $78.00
i
10/30/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$83.00 ➝ $70.00
i
9/10/2020Credit Suisse GroupReiterated RatingBuy
i
7/27/2020Jefferies Financial GroupLower Price TargetBuy$90.00 ➝ $86.00
i
6/10/2020Credit Suisse GroupReiterated RatingBuy$89.00
i
5/29/2020MizuhoLower Price TargetBuy$90.00 ➝ $87.00
i
5/1/2020UBS GroupLower Price TargetBuy$96.00 ➝ $90.00
i
4/30/2020Raymond JamesLower Price TargetOutperform$90.00 ➝ $86.00
i
4/20/2020Royal Bank of CanadaReiterated RatingBuy$84.00
i
4/20/2020BMO Capital MarketsBoost Price TargetOutperform$66.00 ➝ $83.00
i
4/17/2020Credit Suisse GroupReiterated RatingBuy$89.00
i
3/6/2020UBS GroupBoost Price TargetBuy$95.00 ➝ $96.00
i
3/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$73.00 ➝ $83.00
i
3/5/2020BMO Capital MarketsBoost Price TargetOutperform$88.00 ➝ $95.00
i
3/5/2020MizuhoBoost Price TargetBuy$87.00 ➝ $90.00
i
3/5/2020Robert W. BairdBoost Price TargetOutperform$85.00 ➝ $100.00
i
3/5/2020StephensBoost Price TargetOverweight$91.00 ➝ $100.00
i
Rating by Scott Fidel at Stephens
2/10/2020Piper SandlerBoost Price Target$77.00 ➝ $89.00
i
2/10/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$90.00 ➝ $100.00
i
2/10/2020MizuhoReiterated RatingBuy$84.00 ➝ $87.00
i
1/22/2020JMP SecuritiesBoost Price TargetOutperform$85.00
i
1/16/2020MizuhoReiterated RatingBuy$76.00 ➝ $84.00
i
1/15/2020Credit Suisse GroupBoost Price TargetOutperform$77.00 ➝ $89.00
i
1/14/2020BMO Capital MarketsBoost Price TargetOutperform$85.00 ➝ $88.00
i
1/13/2020Jefferies Financial GroupBoost Price Target$80.00 ➝ $90.00
i
1/10/2020UBS GroupBoost Price TargetBuy$80.00 ➝ $87.00
i
12/11/2019Wells Fargo & CompanyDowngradeMarket Perform ➝ Underperform$68.00
i
10/21/2019StephensInitiated CoverageOverweight$77.00
i
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$70.00
i
9/6/2019Bank of AmericaUpgradeNeutral ➝ Buy$73.00
i
8/12/2019Craig HallumReiterated RatingBuy$81.00 ➝ $76.00
i
8/7/2019Royal Bank of CanadaReiterated RatingBuy
i
Rating by Frank Morgan at Royal Bank of Canada
7/31/2019Piper Jaffray CompaniesSet Price TargetBuy$77.00
i
Rating by Sarah James at Piper Jaffray Companies
7/31/2019Raymond JamesLower Price TargetOutperform$80.00 ➝ $75.00
i
6/27/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$72.00
i
5/30/2019BarclaysUpgradeEqual Weight ➝ Overweight$68.00 ➝ $70.00
i
12/20/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy
i
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$75.00
i
11/15/2018UBS GroupInitiated CoverageBuy ➝ Buy$86.00
i
7/26/2018MizuhoReiterated RatingBuy$82.00
i
Rating by Ann Hynes at Mizuho
7/26/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight
i
7/26/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $80.00
i
7/20/2018SunTrust BanksReiterated RatingBuy$82.00
i
4/30/2018Craig HallumReiterated RatingBuy$63.00 ➝ $71.00
i
4/30/2018Royal Bank of CanadaBoost Price TargetOutperform$69.00
i
4/30/2018Robert W. BairdReiterated RatingOutperform$59.00 ➝ $66.00
i
4/27/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $66.00
i
4/17/2018SunTrust BanksReiterated RatingBuy$70.00
i
3/29/2018MizuhoReiterated RatingBuy ➝ Buy$62.00
i
3/16/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$61.00 ➝ $65.00
i
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$59.00
i
3/1/2018Royal Bank of CanadaBoost Price TargetOutperform$64.00
i
2/27/2018StephensSet Price TargetBuy$62.00
i
Rating by Dana Hambly at Stephens
2/27/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $61.00
i
1/30/2018Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$56.00
i
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$58.00
i
1/12/2018StephensReiterated RatingBuy$55.00
i
1/12/2018Robert W. BairdReiterated RatingBuy$59.00
i
12/21/2017SunTrust BanksSet Price TargetBuy$58.00
i
11/21/2017William BlairReiterated RatingOutperform
i
Rating by M. Larew at William Blair
11/15/2017Royal Bank of CanadaReiterated RatingBuy
i
11/2/2017MizuhoUpgradeNeutral ➝ Buy$55.00
i
10/9/2017Robert W. BairdReiterated RatingBuy$55.00
i
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$50.00
i
9/7/2017KeyCorpReiterated RatingHold
i
9/6/2017Royal Bank of CanadaReiterated RatingBuy$55.00
i
8/31/2017StephensInitiated CoverageOverweight$53.00
i
8/3/2017Piper Jaffray CompaniesReiterated RatingHold$50.00
i
7/10/2017MizuhoBoost Price TargetNeutral ➝ Neutral$44.00 ➝ $47.00
i
7/5/2017Royal Bank of CanadaReiterated RatingBuy$53.00
i
6/15/2017KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
i
5/1/2017BarclaysReiterated RatingUnderweight$44.00 ➝ $46.00
i
2/27/2017Royal Bank of CanadaBoost Price TargetOutperform$48.00 ➝ $50.00
i
2/27/2017Royal Bank of CanadaReiterated RatingOutperform$48.00 ➝ $50.00
i
2/22/2017StephensUpgradeEqual Weight ➝ Overweight
i
2/22/2017MizuhoBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $44.50
i
2/13/2017Craig HallumInitiated CoverageBuy$48.00
i
Rating by B. Bonello at Craig Hallum
1/3/2017Piper Jaffray CompaniesInitiated CoverageNeutral$45.00
i
1/3/2017Royal Bank of CanadaReiterated RatingBuy$48.00
i
11/9/2016MizuhoDowngradeBuy ➝ Neutral
i
10/31/2016Royal Bank of CanadaReiterated RatingOutperform$46.00 ➝ $48.00
i
10/31/2016Royal Bank of CanadaBoost Price TargetOutperform$46.00 ➝ $48.00
i
9/11/2016Wells Fargo & CompanyReiterated RatingBuy
i
9/4/2016JMP SecuritiesReiterated RatingBuy
i
Rating by peter martin at JMP Securities
8/22/2016UBS GroupReiterated RatingHold
i
8/1/2016SunTrust BanksSet Price TargetBuy$54.00
i
Rating by David S Macdonald at SunTrust Banks, Inc.
6/27/2016BarclaysDowngradeEqual Weight ➝ Underweight$45.00 ➝ $42.00
i
5/16/2016Robert W. BairdReiterated RatingBuy
i
Rating by Whit Mayo at Robert W. Baird
4/29/2016MizuhoBoost Price TargetBuy$40.00 ➝ $47.00
i
4/28/2016BarclaysBoost Price TargetEqual Weight$39.00 ➝ $45.00
i
(Data available from 3/3/2016 forward)
Encompass Health logo
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and to provide emotional and spiritual support. As of November 16, 2020, Encompass Health Corporation operated 137 hospitals, 242 home health locations, and 83 hospice locations in 39 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

620,391 shs

Average Volume

618,344 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Encompass Health?

The following sell-side analysts have issued stock ratings on Encompass Health in the last twelve months: Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Mizuho, Raymond James, Robert W. Baird, Royal Bank of Canada, Stephens, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for EHC.

What is the current price target for Encompass Health?

11 Wall Street analysts have set twelve-month price targets for Encompass Health in the last year. Their average twelve-month price target is $92.18. UBS Group AG has the highest price target set, predicting EHC will reach $106.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $83.00 for Encompass Health in the next year.
View the latest price targets for EHC.

What is the current consensus analyst rating for Encompass Health?

Encompass Health currently has 1 hold rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EHC will outperform the market and that investors should add to their positions of Encompass Health.
View the latest ratings for EHC.

What other companies compete with Encompass Health?

How do I contact Encompass Health's investor relations team?

Encompass Health's physical mailing address is 3660 Grandview Pkwy Ste 200, BIRMINGHAM, AL 35243-3332, United States. The company's listed phone number is +1-205-9677116 and its investor relations email address is [email protected] The official website for Encompass Health is www.healthsouth.com.